Revance Therapeutics Inc (FRA:RTI)
€ 3.4 -0.1 (-2.86%) Market Cap: 371.12 Mil Enterprise Value: 655.05 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 68/100

Q2 2024 Revance Therapeutics Inc Earnings Call Transcript

Aug 08, 2024 / 08:30PM GMT
Release Date Price: €2.62 (-7.75%)
Operator

Welcome to the Revance Therapeutics second-quarter 2024 financial results and corporate update conference call. (Operator Instructions) As a reminder, this call is being recorded today, Thursday, August 8, 2024.

I will now hand the call over to your host, Laurence Watts with Revance Therapeutics. Please proceed.

Laurence Watts
New Street IR - Investor Relations

Thank you operator. Joining us on the call today from Revance are President and Chief Executive Officer, Mark Foley; and Chief Financial Officer, Tobin Schilke.

During this call, management will make forward-looking statements, including statements related to expectations related to product adoption and reorders, consumer needs, preferences and behavior, the benefits and value to us, practices, and consumers of our products, including the efficacy, duration, skin quality, and safety of our products, future therapeutics expansion, 2024 guidance, positive adjusted EBITDA, future capital expenditures and anticipated revenue, our strategic priorities, our anticipated success, our ability

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot